HEMOGENYX PHARMACEUTICALS PLC Logo

HEMOGENYX PHARMACEUTICALS PLC

Develops CAR-T therapies for blood cancers, autoimmune disorders, and viral infections.

HEMO | IL

Overview

Corporate Details

ISIN(s):
GB00BYX3WZ24
LEI:
2138008L93GYU5GN6179
Country:
United Kingdom
Address:
6TH FLOOR, 60 GRACECHURCH STREET, EC3V 0HR LONDON
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Hemogenyx Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapies for life-threatening diseases. The company develops new medicines and treatments targeting blood diseases, autoimmune disorders, and viral infections. Its pipeline includes immunotherapy product candidates, such as CAR-T cell therapies, for the treatment of blood malignancies like acute myeloid leukemia (AML). Hemogenyx is dedicated to creating breakthrough treatments to address significant unmet medical needs, including improving the safety and efficacy of bone marrow transplantation.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-29 08:00
Regulatory News Service
Clinical Trial Update and Grant of Share Awards
English 18.6 KB
2025-09-23 08:00
Regulatory News Service
Hemogenyx Signs Letter of Intent
English 17.6 KB
2025-09-18 14:16
Major Shareholding Notification
Holding(s) in Company
English 60.2 KB
2025-09-17 08:00
Legal Proceedings Report
Third Patient Safety
English 16.5 KB
2025-09-11 08:00
Regulatory News Service
Invitation to Participate at DCNY Summit
English 11.6 KB
2025-09-08 08:00
Regulatory News Service
Manufacturing Partnership with Made Scientific
English 13.2 KB
2025-09-03 14:57
Share Issue/Capital Change
Exercise of Warrants and Issue of Equity
English 11.8 KB
2025-08-15 08:00
Regulatory News Service
Third Patient Treated with HG-CT-1 CAR-T Therapy
English 12.2 KB
2025-07-31 08:00
Declaration of Voting Results & Voting Rights Announcements
Total Voting Rights
English 10.1 KB
2025-07-29 09:00
Share Issue/Capital Change
Placing to Raise £250,000 and Director’s Dealing
English 26.5 KB
2025-07-16 08:00
Regulatory News Service
Hemogenyx Awarded Grant
English 14.6 KB
2025-06-30 08:00
Declaration of Voting Results & Voting Rights Announcements
Total Voting Rights
English 9.6 KB
2025-06-03 15:02
Director's Dealing
Placing to Raise £451,250 and Director’s Dealing
English 26.1 KB
2025-06-03 08:00
Legal Proceedings Report
Second Patient Passes Initial Safety Tests
English 14.9 KB
2025-05-31 12:30
Post-Annual General Meeting Information
Resolutions passed at Annual General Meeting of Hemogenyx Pharmaceuticals plc o…
English 33.9 KB

Automate Your Workflow. Get a real-time feed of all HEMOGENYX PHARMACEUTICALS PLC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for HEMOGENYX PHARMACEUTICALS PLC

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for HEMOGENYX PHARMACEUTICALS PLC via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Active Biotech Logo
Develops immunology-based drugs for cancer and inflammatory diseases with high unmet medical need.
Sweden ACTI
ACTUATE THERAPEUTICS, INC. Logo
Clinical-stage biopharma developing a novel GSK-3 inhibitor for hard-to-treat cancers.
United States of America ACTU
AcuCort AB Logo
Develops a rapid oral film for acute allergies, croup, and chemo-induced nausea.
Sweden ACUC
Acurx Pharmaceuticals, Inc. Logo
Developing a new class of antibiotics to treat priority Gram-positive bacterial infections.
United States of America ACXP
Adagene Inc. Logo
Develops novel antibody-based immunotherapies for cancer using an AI-driven discovery platform.
United States of America ADAG
Adaptimmune Therapeutics PLC Logo
Develops novel T-cell therapies to treat solid tumors by engineering a patient's own immune cells.
United States of America ADAP
ADBIOTECH Co.,Ltd. Logo
Develops egg-based IgY antibodies as vaccine/antibiotic alternatives for animal and human health.
South Korea 179530
ADC Therapeutics SA Logo
Develops targeted antibody-drug conjugates for hematological and solid tumors.
United States of America ADCT
Addex Therapeutics Ltd. Logo
Developing novel oral allosteric modulators to treat neurological disorders.
United States of America ADXN
ADIAL PHARMACEUTICALS, INC. Logo
Develops personalized, genetically-targeted drugs for treating Alcohol Use Disorder and addiction.
United States of America ADIL

Talk to a Data Expert

Have a question? We'll get back to you promptly.